Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lantheus Holdings, Inc. - Common Stock (NQ:LNTH)

57.20 0.00 (0.00%)
Streaming Delayed Price 8:00:00 PM GMT, Aug 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Lantheus Holdings, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Lantheus Reports Second Quarter 2025 Financial Results and Provides Business Update
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Announces FDA Acceptance of NDA for New Formulation for Market-Leading PSMA PET Imaging Agent
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus to Host Second Quarter 2025 Earnings Conference Call and Webcast on August 6, 2025, at 8:00 a.m. Eastern Time
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Completes Acquisition of Life Molecular Imaging and Appoints Dr. Ludger Dinkelborg as Head of R&D
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Announces Presentations to be featured at the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus to Present at the 2025 Truist Securities MedTech Conference
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Holdings, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - LNTH
From DJS Law Group
Via Business Wire
Lantheus Reports First Quarter 2025 Financial Results and Provides Business Update
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Announces Sale of SPECT Business to SHINE Technologies
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Announces Alzheimer’s Disease Radiodiagnostic MK-6240 Meets Co-Primary Endpoints in Two Pivotal Studies
Company plans to file NDA in the third quarter of this year 
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus to Host First Quarter 2025 Earnings Conference Call and Webcast on May 7, 2025, at 8:00 a.m. Eastern Time
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Completes Acquisition of Evergreen Theragnostics
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Reports Fourth Quarter and Full Year 2024 Financial Performance
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus to Present at Upcoming Investor Conferences
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus to Host Fourth Quarter and Full Year 2024 Earnings Conference Call and Webcast on February 26, 2025, at 8:00 a.m. Eastern Time
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Announces Presentations Featuring PYLARIFY (Piflufolastat F 18) Data at the ASCO GU Meeting
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Appoints Phuong Khanh (P.K.) Morrow, M.D., as New Board Member
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $250 Million to Drive Strategic Evolution into Fully Integrated Radiopharmaceutical Leader
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus to Acquire Life Molecular Imaging for an Upfront Payment of $350 Million to Accelerate Innovation for Patients in the Growing Alzheimer’s Disease Radiodiagnostic Market
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Announces Share Repurchase Program
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus to Present at the Jefferies London Healthcare Conference
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Continues to Commend CMS’ CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals and Reaffirms Outlook for PYLARIFY’s Blockbuster Status for 2025
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Reports Third Quarter 2024 Financial Results
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Applauds CMS’ CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals, Advancing Patient Access and Care
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus to Host Third Quarter 2024 Earnings Conference Call and Webcast on November 6, 2024, at 8:00 a.m. Eastern Time
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Appoints Julie Eastland as New Board Member
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus to Present Additional Clinical Data from Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024
From Lantheus Holdings, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.